The FDA has approved the Vanquish Water Vapor Ablation System, which uses steam to destroy prostate tumors. However, the efficacy of the device in eliminating cancer has yet to be established, according to the manufacturer, Francis Medical, Inc.

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Prostate cancer is one of the most common cancers affecting men, especially over the age of 50. As per the American Cancer Society’s Prostate Cancer Statistics 2025 report, prostate cancer cases in the United States have shifted direction.

Francis Medical is heating up with a 510 (k) clearance from the FDA for its water vapor ablation therapy aimed at cancers of the prostate, kidneys and bladder. The regulatory go-ahead for its Vanquish system was buoyed by a follow-up clinical study that involved 110 patients, the company said in a Dec. 2 press release.

Sir Chris Hoy’s stage-four diagnosis has put prostate cancer under the spotlight among cyclists. Cycling Weekly tackles the confusion around risk factors and screening

Burley Brewton was able to count on a new advancement in targeted therapy after he was diagnosed with prostate cancer, the second most common cancer in men.

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests.

The Taiwanese veteran disclosed he underwent surgery in 2018 as well as radiation therapy. Read more at straitstimes.com. Read more at straitstimes.com.

Currently on crutches, Hoy confirmed that he had broken his leg in the crash but is recovering at a pace that will allow him to be at the World Darts Championship final at the turn of the year.

5. This is NOT a death sentence. I know, any form of cancer can be lethal. I also know that prostate cancer is one of the more treatable and survivable forms of cancer. In the past few months, I've heard stories about a long list of people who have lived many years after their diagnosis.

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd (DRTS) has recently completed a clinical study titled ‘A Feasibility of Neoadjuvant Interstitial Brachytherapy (Ibt) Using Diffusing Alpha Emitters ...